Link to this page
Biological and Environmental Research Ontology
| Id | http://purl.obolibrary.org/obo/NCIT_C1383
http://purl.obolibrary.org/obo/NCIT_C1383
|
|---|---|
| Preferred Name | Liposomal NDDP |
| Definitions |
A synthetic liposomal formulation of bis-neodecanoate diaminocyclohexane platinum (NDDP), a third-generation platinum complex analogue of cisplatin, with potential antineoplastic activity. After displacement of the 2 long-chain aliphatic leaving groups (neodecanoic acid), platinum diaminocyclohexane (DACH) complexes become highly reactive and alkylate macromolecules, forming both inter- and intra-stranded DNA cross-linkings and inhibiting DNA synthesis, which results in tumor cell cytotoxicity. Because DNA mismatch-repair (MMR) complexes do not recognize DACH-platinum adducts, DNA repair mechanisms are inhibited, overcoming limitations observed with other platinum-based agents. In addition, the liposomal encapsulation improves the bioavailability of NDDP and reduces its toxicity profile.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A synthetic liposomal formulation of bis-neodecanoate diaminocyclohexane platinum (NDDP), a third-generation platinum complex analogue of cisplatin, with potential antineoplastic activity. After displacement of the 2 long-chain aliphatic leaving groups (neodecanoic acid), platinum diaminocyclohexane (DACH) complexes become highly reactive and alkylate macromolecules, forming both inter- and intra-stranded DNA cross-linkings and inhibiting DNA synthesis, which results in tumor cell cytotoxicity. Because DNA mismatch-repair (MMR) complexes do not recognize DACH-platinum adducts, DNA repair mechanisms are inhibited, overcoming limitations observed with other platinum-based agents. In addition, the liposomal encapsulation improves the bioavailability of NDDP and reduces its toxicity profile. |
|---|---|
| prefLabel | Liposomal NDDP
|
| label | Liposomal NDDP
|
| PDQ_Closed_Trial_Search_ID | 43010
|
| code | C1383
|
| Has_Target | |
| prefixIRI | NCIT:C1383
|
| in_subset | |
| Preferred_Name | Liposomal NDDP
|
| FDA_UNII_Code | J7M4Z2D183
|
| Contributing_Source | FDA
|
| Maps_To | Liposomal NDDP
|
| CAS_Registry | 114488-24-3
|
| NCI_Drug_Dictionary_ID | 43010
|
| Legacy Concept Name | Liposomal-Cisplatin_Analogue
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 43010
|
| Semantic_Type |
Organic Chemical
Pharmacologic Substance
|
| UMLS_CUI | C0125061
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |